Treatment Options for Diffuse Large B-cell Lymphoma

This chapter explores different treatment regimens for refractory diffuse large B-cell lymphoma, including R-ICE, R-DHAP, GDP, anti-CD19 CAR T therapy, polatuzumab, gemcitabine, oxaliplatin, tafasitamab, selinexor, loncastuximab, and allogeneic stem cell transplant. It emphasizes the importance of testing the disease's biology and using refractory chemo regimens before considering an auto stem cell transplant, as well as the need for more intense treatment in certain subsets of patients. The recommended follow-up protocol for cured patients is also covered.